4-氟-3-(三氟甲基)苯甲酸甲酯 | 176694-36-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氟-3-(三氟甲基)苯甲酸甲酯
• 中文别名: 4-氟-3-三氟甲基苯甲酸甲酯
• 英文名称: methyl 4-fluoro-3-(trifluoromethyl)benzoate
• 英文别名: 4-fluoro-3-trifluoromethyl-benzoic acid methyl ester
• CAS: 176694-36-3
• 化学式: C₉H₆F₄O₂
• 分子量: 222.139
• InChiKey: IRYBOHVMFKZODT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2916399090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温且干燥

反应信息

• 作为反应物：
  描述：

  4-氟-3-(三氟甲基)苯甲酸甲酯 在 potassium carbonate 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 反应 0.5h， 生成 4-{3-[(1H-pyrrole-2-carbonyl)amino]pyrrolidin-1-yl}-3-trifluoromethylbenzoic acid methyl ester
  参考文献：
  名称：

  Identification of a Potent Sodium Hydrogen Exchanger Isoform 1 (NHE1) Inhibitor with a Suitable Profile for Chronic Dosing and Demonstrated Cardioprotective Effects in a Preclinical Model of Myocardial Infarction in the Rat

  摘要：

  Sodium-hydrogen exchanger isoform 1 (NHE1) is a ubiquitously expressed transmembrane ion channel responsible for intracellular pH regulation. During myocardial ischemia, low pH activates NHE1 and causes increased intracellular calcium levels and aberrant cellular processes, leading to myocardial stunning, arrhythmias, and ultimately cell damage and death. The role of NHE1 in cardiac injury has prompted interest in the development of NHE1 inhibitors for the treatment of heart failure. This report outlines our efforts to identify a compound suitable for once daily, oral administration with low drug-drug interaction potential starting from NHE1 inhibitor sabiporide. Substitution of a piperidine for the piperazine of sabiporide followed by replacement of the pyrrole moiety and subsequent optimization to improve potency and eliminate off-target activities resulted in the identification of N-[4-(1-acetyl-piperidin-4-yl)-3-trifluoromethyl-benzoyl]-guanidine (60). Pharmacological evaluation of 60 revealed a remarkable ability to prevent ischemic damage in an ex vivo model of ischemia reperfusion injury in isolated rat hearts.

  DOI：

  10.1021/jm300601d
• 作为产物：
  描述：

  4-氟-3-(三氟甲基)苯甲酸 在 氯化亚砜 作用下， 以 甲醇 为溶剂， 生成 4-氟-3-(三氟甲基)苯甲酸甲酯
  参考文献：
  名称：

  SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT OR DIAGNOSTIC AND MEDICAMENT COMPRISING THE SAME

  摘要：

  本发明涉及式I的取代苯甲酰胍类化合物： 其中R1至R8和X和Y如规范中所述，并且它们的药用盐是细胞钠质子抗体转运蛋白(Na+/H+交换蛋白，NHE)的取代酰胍类化合物抑制剂。

  公开号：

  US20070270414A1

文献信息

• [EN] 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES<br/>[FR] DÉRIVÉS DE 9-AMINOACRIDINE, LEUR PRÉPARATION ET LEURS UTILISATIONS
  申请人：UNIV ARIEL RES & DEV CO LTD

  公开号：WO2011051950A1

  公开（公告）日：2011-05-05

  N-substituted 9-aminoacridine and bis-acridino derivatives containing electron- withdrawing groups (EWG) or electron-donating groups (EDG), including amino acid residues, and one-pot methods for their synthesis are disclosed. The derivatives are potential candidates for cancer treatment.

  含有取代基的9-氨基吖啶和含有电子吸引基团（EWG）或电子供给基团（EDG）的双吖啶衍生物，包括氨基酸残基，以及它们的合成的一锅法被披露。这些衍生物是潜在的癌症治疗候选物。
• Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors
  申请人：Ackermann Jean

  公开号：US20070191603A1

  公开（公告）日：2007-08-16

  The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.

  这项发明涉及公式（I）的新异双环衍生物，其中R1、R2、R3、R4、R5、R6、V、W、X和Y的定义如描述和索赔中所述，以及其生理上可接受的盐和酯。这些化合物抑制L-CPT1，可用作药物。
• Thymidine analogs for imaging
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1916003A1

  公开（公告）日：2008-04-30

  The present invention relates to nucleoside analogues and more particularly to labelled nucleoside analogues of formula (I). It has been found new thymidine analogues can be stably labelled with a detectable label moiety. Further the present invention relates to methods of making above compounds and use of such compounds for diagnostic imaging of tumor cells and I or treatment of proliferative diseases. In addition, the present invention relates to the preparation and use of positron emitting compounds for positron emission tomography (PET). A kit is also disclosed.

  本发明涉及核苷类似物，更特别地涉及式(I)的标记核苷类似物。已发现新的胸苷类似物可以稳定地标记具有可检测标记基团。此外，本发明涉及制备上述化合物的方法以及利用这些化合物进行肿瘤细胞的诊断成像和/或治疗增殖性疾病。此外，本发明涉及制备和使用正电子发射化合物进行正电子发射断层扫描（PET）。还公开了一种试剂盒。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：UCL BUSINESS LTD

  公开号：WO2020043866A1

  公开（公告）日：2020-03-05

  A compound for use in the treatment of a disease ameliorated by the inhibition of Notum of formula (I): (I)

  一种用于治疗通过抑制公式（I）中的Notum改善的疾病的化合物：（I）
• [EN] FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS<br/>[FR] COMPOSÉS AMIDES TRICYCLIQUES CONDENSÉS COMME INHIBITEURS DE KINASES MULTIPLES
  申请人：BEIGENE LTD

  公开号：WO2014206344A1

  公开（公告）日：2014-12-31

  Provided are fused tricyclic amide compounds, pharmaceutical compositions comprising at least one such fused tricyclic compound, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain tricyclic amide compounds that can be useful for inhibiting multiple (specifically BRAF and/or EGFR-T790M) kinases and for treating disorders mediated thereby.

  提供了融合的三环酰胺化合物，包括至少一种这样的融合三环化合物的药物组合物，其制备方法以及在治疗中的使用。本文披露了某些三环酰胺化合物，可以用于抑制多种（特别是BRAF和/或EGFR-T790M）激酶，并用于治疗由此介导的疾病。